<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>MLF1 is a novel protein identified as the NPM-MLF1 chimeric protein produced by a t(3;5)(q25.1;q34) chromosomal translocation, which is associated with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), often prior to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), except for M3 </plain></SENT>
<SENT sid="1" pm="."><plain>The clinical features of t(3;5)-positive myeloid disorders suggest that this chimeric protein is involved in dysregulation of progenitor cells with the capability to differentiate into multiple lineages </plain></SENT>
<SENT sid="2" pm="."><plain>So far, involvement of <z:mp ids='MP_0002169'>wild-type</z:mp> MLF1 in hematopoiesis or in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> has not been fully investigated </plain></SENT>
<SENT sid="3" pm="."><plain>In the present study, 65 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 44 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were tested for the expression of MLF1 using the quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) method </plain></SENT>
<SENT sid="4" pm="."><plain>A significantly higher level of MLF1 expression (ratio of MLF1/beta-actin <z:chebi fb="2" ids="33699">mRNA</z:chebi> &gt;0.4) was readily detected in seven of 65 patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, three of 12 with post-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and seven of 44 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, but not in any patients with ALL (n = 18) </plain></SENT>
<SENT sid="5" pm="."><plain>According to the FAB classification, high levels of MLF1 were found in patients with relatively immature subtypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (M1, M2, M6 and M7) and high risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) </plain></SENT>
<SENT sid="6" pm="."><plain>These findings indicate that the pattern of MLF1 expression is identical to the clinical <z:mp ids='MP_0000002'>morphology</z:mp> appearing in the t(3;5)-positive myeloid disorders and is correlated to the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-associated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and transformation phase of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in t(3;5)-negative myeloid disorders </plain></SENT>
<SENT sid="7" pm="."><plain>A CD34+ population of <z:mpath ids='MPATH_458'>normal</z:mpath> bone marrow cells preferentially expressed MLF1 with obviously decreasing levels of expression during maturation </plain></SENT>
<SENT sid="8" pm="."><plain>Therefore, MLF1 normally functions in multi-potent progenitor cells and its dysregulation may take part in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>